Rmeex Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.50 M
- Revenue Growth 112.72%
- Profit Growth 93.49%
- Ebitda 144.75%
- Net Worth -8.27%
- Total Assets 282.93%
About Rmeex Pharmaceutical
Rmeex Pharmaceutical Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 July 2013 and has a history of 11 years and six months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.50 M.
Pratap Nayak and Rajesh Dash serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74900KA2013PTC070356
- Company No.
070356
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Rmeex Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pratap Nayak  | Director | 29-Jul-2013 | Current |
| Rajesh Dash | Director | 29-Jul-2013 | Current |
Financial Performance of Rmeex Pharmaceutical.
Rmeex Pharmaceutical Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 112.72% increase. The company also saw a substantial improvement in profitability, with a 93.49% increase in profit. The company's net worth dipped by a decrease of 8.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rmeex Pharmaceutical?
In 2020, Rmeex Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Uprise Staff Solutions Private LimitedPratap Nayak is a mutual person
G2evolution Private LimitedRajesh Dash is a mutual person
Neotric Pharmaceutical LlpPratap Nayak is a mutual person
Charges (Loans)
₹3.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.35 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Feb 2024 | Others | ₹3.50 M | Open |
How Many Employees Work at Rmeex Pharmaceutical?
Unlock and access historical data on people associated with Rmeex Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rmeex Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rmeex Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.